Company name: ECaBox
EU Contribution: € 3 552 144
Location: Spain

ECaBox is a breakthrough platform that keeps whole eyes alive outside the body, recreating human relevant conditions to test ophthalmic drugs and cutting edge gene and cell therapies. By offering a more predictive, ethical alternative to pre-clinical animal and simplified lab model systems, it can accelerate safer treatments for vision loss, reduce failed clinical trials, and bring new hope to patients, while opening future possibilities for eye preservation and, ultimately, eye transplantation.
Vision & ImpactECaBox aims to transform how vision therapies are developed by enabling human relevant and ethical research. It seeks to bring safer and more effective eye treatments to patients and, in the long term, lays the foundations for eye preservation for eye transplantation.
CollaborationThe EIC has provided not only funding, but strategic guidance and access to a strong innovation ecosystem. Through portfolio activities and networking, we gained valuable feedback, new collaborations and a clearer view of how research can evolve towards real-world impact.
What's next ?Looking ahead, we will continue to explore how ECaBox can support research on complex eye diseases and emerging therapies. Alongside validation and collaboration, we are working to enable its uptake in real world settings, so that this approach can benefit patients in a responsible and robust way.

EIC support has given us the opportunity to pursue a bold dream that, just a few years ago, felt almost impossible: reviving an eye and preserving it outside the body for ex vivo testing of new therapies. Today, with the ECaBox system, that dream has become a reality. We can now keep whole, human and human like eyes alive, and even work with multiple eyes in parallel, to better understand vision and develop safer treatments. This work reflects a broader European ambition to advance more ethical, human relevant science, in clear alignment with priorities such as the 3Rs and New Approach Methodologies. We see a future in which pioneering science, ethics and patient therapy development progress together, reinforcing one another throughout the development process. We are thrilled by these possibilities, which will be catalysed by the continued support of the EIC. We look forward to the discoveries, achievements, and impact that lie ahead.
ECaBox's Timeline
- 2021 - 2025EIC Pathfinder
Foundation of the ECaBox concept and ex vivo eye-maintenance workflow.
Scientific validation of the platform for eyemaintenance in laboratory settings
7 ECaBox outcomes recognised by the EuropeanCommission’s Innovation Radar
ECaBox recognised in a CORDIS "Results in Brief"article for its contribution to advancing preclinicalophthalmic research
- 2025 - 2027Spanish National Research Agency Grant
Proof-of-concept phase:optimisation, robustness, andtranslational positioning
Pharma pilot studies
Launched
- 2025EIC Transition
Seal of Excellence Awardee
- 2026+New Company funded
Matured business plan, regulatory strategy, team structure and spin-off route